15

20

25

What is claimed is:

1. A substantially purified human integral membrane protein comprising the amino acid sequence of SEQ ID NO:1 or fragments thereof.

2. A substantially purified variant of human integral membrane protein having at least 90% amino acid identity to SEQ ID NO:1 and which retains at least one functional characteristic of human integral membrane protein.

An isolated and purified polynucleotide sequence encoding the human integral membrane protein of claim 1 or fragments or variants of said polynucleotide sequence.

- 4. A composition comprising the polynucleotide sequence of claim 3.
- 5. A polynucleotide sequence which hybridizes to the polynucleotide sequence of claim 3.
- 6. A polynucleotide sequence which is complementary to the polynucleotide sequence of claim 3 or fragments or variants thereof.
- 7. An isolated and purified polynucleotide sequence comprising SEQ ID NO:2 or fragments or variants thereof.
- 8. A polynucleotide sequence which is complementary to the polynucleotide sequence of claim 7.
 - 9. An expression vector containing at least a fragment of the polynucleotide sequence of claim 3.
- 30 10. A host cell containing the vector of claim 9.

PF-0339 US

- A method for producing a polypeptide comprising the amino acid sequence of 11. SEQ ID NO:1, or a fragment there of; the method comprising the steps of:
 - culturing the host cell of claim 10 under conditions suitable for the expression of the polypeptide, and
 - recovering/the polypeptide from the host cell culture.
- A pharmaceutical composition comprising a substantially purified human 12. integral membrane protein having the amino acid sequence of SEQ ID NO:1 in conjunction with a suitable pharmaceutical carrier.
 - A purified antibody which specifically binds to the polypeptide of claim 1. 13.
 - 14. A purified agonist of the polypeptide of claim 1.
 - A purified antagonist of the polypeptide of claim 1. · 15.
- A method for treating cancer comprising administering to a subject in need of 16. such treatment an effective amount of the pharmaceutical composition of claim 12.
- A method for treating a neuronal disorder comprising administering to a 17. subject in need of such treatment an/effective amount of the antagonist of claim 15.
- A method for treating an immunological disorder comprising administering to 18. a subject in need of such treatment an effective amount of the antagonist of claim 15
- 19. A method for detecting a polynucleotide which encodes human integral membrane protein in a biological sample comprising the steps of:
 - hybridizing the polynucleotide of claim 6 to nucleic acid material of a a) biological sample, thereby forming a hybridization complex; and
 - b) detecting said hybridization complex, wherein the presence of said

15

5

20

25

PF-0339 US

complex correlates with the presence of a polynucleotide encoding human integral membrane protein in said biological sample.

20. The method of claim 19 wherein the nucleic acid material is amplified by the polymerase chain reaction prior to hybridization.

add Def